0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cilnidipine"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Calcium Channel Blocker Market Report 2025 - Product Thumbnail Image

Calcium Channel Blocker Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Raynauds Disease Treatment Global Market Report 2025 - Product Thumbnail Image

Raynauds Disease Treatment Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
EUR$4,490USDGBP
  • 3 Results (Page 1 of 1)
Loading Indicator

Cilnidipine is a calcium channel blocker used to treat hypertension and other cardiovascular diseases. It is a dihydropyridine derivative that works by blocking the influx of calcium ions into the smooth muscle cells of the heart and blood vessels, resulting in a decrease in blood pressure. Cilnidipine is available in both oral and intravenous formulations. It is generally well tolerated, with few side effects. Cilnidipine is a relatively new drug in the cardiovascular market, but it has been gaining traction in recent years due to its efficacy and safety profile. It is increasingly being used as an alternative to other calcium channel blockers, such as amlodipine and nifedipine, due to its lower risk of side effects. Some of the major companies in the cilnidipine market include Sun Pharmaceuticals, Lupin Pharmaceuticals, Dr. Reddy's Laboratories, and Glenmark Pharmaceuticals. These companies are involved in the production, marketing, and distribution of cilnidipine products. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more